UPDATE: Kura Oncology (KURA) Tops Q1 EPS by 1c; Expands Enrollment in Phase 2 Trial of Tipifarnib
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Kura Oncology Reports Second Quarter 2016 Financial Results
August 10, 2016 4:03 PM EDTPromising clinical activity observed in Phase 2 trial of tipifarnib in HRAS mutant solid tumors has triggered additional patient enrollment
Management to host webcast and conference call today at 1:15 p.m. PDT/4:15 p.m. EDT
LA JOLLA, Calif., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., (NASDAQ: KURA) a clinical stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported second quarter 2016 financial results and recent business highlights. In the companys Phase 2 trial of tipifarnib in HRAS mutant solid... More
